Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer.

Purpose Of The Review: This review paper is a comprehensive look at the cardiovascular disease (CVD) risk that is associated with the use of androgen deprivation therapy in prostate cancer. It summarizes when certain cancer therapies are indicated and should guide physicians in identifying patients at increased risk for CVD during prostate cancer therapy.

Recent Findings: GnRH agonist use and maximal androgen blockade (MAB) are associated with increased CVD.

Tyrosine Kinase Inhibitor-Induced Hypertension.

Purpose Of Review: The purpose of this paper is to identify commonly used tyrosine kinase inhibitors (TKIs) that are associated with hypertension, primarily, vascular endothelial growth factor (VEGF) signaling pathway (VSP) inhibitors. We review the incidence, mechanism, and strategies for management of TKI-induced HTN. We hope to provide clinicians with guidance on how to manage similar clinical scenarios.